Head and neck cancer is the sixth most common cancer worldwide. At present, globally
about 650,000 new cases of squamous cell carcinoma of the head and neck (SCCHN) are …

OBJECTIVE: Worldwide, head and neck carcinomas account for 5% of all malignancies.
Two-thirds of patients relapse after initial multimodal therapy. Until early 2000, the median …

The addition of cetuximab (CTX) to the combination of cisplatin and 5-fluorouracil increases
the overall survival (OS) in recurrent/metastatic head and neck squamous cell carcinoma …

Nimotuzumab is a humanized anti-EGFR IgG1 monoclonal antibody and demonstrates a
better safety profile than other anti-EGFR antibodies due to its intermediate affinity. Since it …

Current development of molecular targeted therapies in oncology is particularly active. This
paper is a review of the recent advances in the field of molecular targeted therapies for head …

The epidermal growth factor receptor (EGFR) is overexpressed in the vast majority of cases
of squamous cell carcinoma of the head and neck (SCCHN). A high EGFR expression is …

Монография посвящена проблеме изучения молекулярного патогенеза
плоскоклеточного рака головы и шеи. Подробно проанализированы современные …

Targeting of the EGF receptor (EGFR) has become a standard of care in several tumor types.
In squamous cell carcinoma of the head and neck, monoclonal antibodies directed against …

Background Deregulation of cell-cycle pathway is ubiquitously observed in human
papillomavirus negative (HPVneg) head and neck squamous cell carcinoma (HNSCC) …

The multidisciplinary approach is becoming the standard for treatment of advanced head
and neck cancer. Combined modality treatment preserves quality of life as well as improving …